---
figid: PMC7429799__13014_2020_1638_Fig2_HTML
figtitle: How oncometabolites can modulate radiosensitivity
organisms:
- Homo sapiens
- Mus musculus
- Saccharomyces cerevisiae
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7429799
filename: 13014_2020_1638_Fig2_HTML.jpg
figlink: pmc/articles/PMC7429799/figure/Fig2/
number: F2
caption: Schematic representation of how oncometabolites can modulate radiosensitivity.
  The indicated oncometabolites (orange) can accumulate as a consequence of mutations
  of TCA cycle enzymes or environmental cues, such as hypoxia and even without oncogenic
  mutations e.g. by pharmacologic inhibition of SLC25A1. 2-HG, succinate and fumarate
  induce metabolic reprogramming and a “pseudo-hypoxic phenotype” via stabilisation
  of HIF1α. Moreover, indicated oncometabolites are competitive inhibitors of the
  αKG-dependent KDM and TET families of epigenetic enzymes, thereby modulating DNA
  repair and pathway choice and offer novel therapeutic opportunities with IR. αKG = α-Ketoglutarate,
  C = cytosine, K = Lysin, L/D-2-HG = L/D-2-hydroxyglutarate, mt = mutant, Orange
  colour represents increased metabolite levels
papertitle: Oncometabolites and the response to radiotherapy.
reftext: Kexu Xiang, et al. Radiat Oncol. 2020;15:197.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9030972
figid_alias: PMC7429799__F2
figtype: Figure
redirect_from: /figures/PMC7429799__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7429799__13014_2020_1638_Fig2_HTML.html
  '@type': Dataset
  description: Schematic representation of how oncometabolites can modulate radiosensitivity.
    The indicated oncometabolites (orange) can accumulate as a consequence of mutations
    of TCA cycle enzymes or environmental cues, such as hypoxia and even without oncogenic
    mutations e.g. by pharmacologic inhibition of SLC25A1. 2-HG, succinate and fumarate
    induce metabolic reprogramming and a “pseudo-hypoxic phenotype” via stabilisation
    of HIF1α. Moreover, indicated oncometabolites are competitive inhibitors of the
    αKG-dependent KDM and TET families of epigenetic enzymes, thereby modulating DNA
    repair and pathway choice and offer novel therapeutic opportunities with IR. αKG = α-Ketoglutarate,
    C = cytosine, K = Lysin, L/D-2-HG = L/D-2-hydroxyglutarate, mt = mutant, Orange
    colour represents increased metabolite levels
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Gnat2
  - fh
  - oh
  - Sord
  - Aass
  - Sds
  - Hif1a
  - H1-0
  - H1-1
  - H1-2
  - H1-3
  - H1-4
  - H1-5
  - H1-6
  - H1-7
  - H1-8
  - H1-10
  - .na.character
  - H2AB1
  - H2AJ
  - H2AZ2
  - H2AX
  - MACROH2A1
  - MACROH2A2
  - H2AZ1
  - H2AC1
  - H2AC6
  - H2AC7
  - H2AC12
  - H2AC14
  - H2AC21
  - H2AC20
  - H2AC25
  - H2BC1
  - H2BC3
  - H2BC5
  - H2BC9
  - H2BC11
  - H2BC12
  - H2BC13
  - H2BC14
  - H2BC15
  - H2BC17
  - H2BC18
  - H2BC19P
  - H2BC20P
  - H2BC21
  - H2BC26
  - H2BC12L
  - H2BW2
  - H2BW1
  - H3-4
  - H3-5
  - H4C7
  - FH
  - SARDH
  - SDHB
  - SORD
  - SDS
  - PDC
  - HIF1A
  - Me
  - CycE
  - cyc
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - LKRSDH
  - SdhB
  - SdhA
  - Sodh-2
  - SdhC
  - ph-d
  - Hph
  - sima
  - pyruvate
  - oxalacetate
  - citrate
  - 'L-2-HG  Me '
  - TCA
  - 'succinate  Me '
  - Hypoxia
  - hypoxia
  - toxicity
---
